- Home
- SMID vs IKT Comparison
SMID vs IKT Comparison
Compare SMID & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMID
- IKT
- Stock Information
- Founded
- SMID 1960
- IKT 2008
- Country
- SMID United States
- IKT United States
- Employees
- SMID N/A
- IKT N/A
- Industry
- SMID Building Materials
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- SMID Industrials
- IKT Health Care
- Exchange
- SMID Nasdaq
- IKT Nasdaq
- Market Cap
- SMID 157.4M
- IKT 140.5M
- IPO Year
- SMID 1995
- IKT 2020
- Fundamental
- Price
- SMID $36.79
- IKT $1.84
- Analyst Decision
- SMID
- IKT Buy
- Analyst Count
- SMID 0
- IKT 2
- Target Price
- SMID N/A
- IKT $8.00
- AVG Volume (30 Days)
- SMID 21.3K
- IKT 521.3K
- Earning Date
- SMID 07-10-2025
- IKT 08-13-2025
- Dividend Yield
- SMID N/A
- IKT N/A
- EPS Growth
- SMID 444.88
- IKT N/A
- EPS
- SMID 1.86
- IKT N/A
- Revenue
- SMID $84,450,000.00
- IKT N/A
- Revenue This Year
- SMID N/A
- IKT N/A
- Revenue Next Year
- SMID N/A
- IKT N/A
- P/E Ratio
- SMID $20.71
- IKT N/A
- Revenue Growth
- SMID 33.01
- IKT N/A
- 52 Week Low
- SMID $25.13
- IKT $1.12
- 52 Week High
- SMID $51.96
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- SMID 69.87
- IKT 47.64
- Support Level
- SMID $35.07
- IKT $1.76
- Resistance Level
- SMID $39.02
- IKT $1.94
- Average True Range (ATR)
- SMID 1.72
- IKT 0.15
- MACD
- SMID 0.42
- IKT 0.00
- Stochastic Oscillator
- SMID 83.71
- IKT 50.98
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.